<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04719650</url>
  </required_header>
  <id_info>
    <org_study_id>M2020427</org_study_id>
    <nct_id>NCT04719650</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid</brief_title>
  <official_title>The Pharmacokinetics and Pharmacodynamics Study of Intravenous Zoledronic Acid in Chinese Subjects With Low Bone Mass or Osteoporosis: a Randomized Placebo-controlled Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The recommended dosing regimen of zoledronic acid in Chinese osteoporosis patients is&#xD;
      completely in accordance with the one of 5 mg per year abroad that based on the dosing&#xD;
      regimen in Paget's disease. This dosing regimen lacks the actual supportive clinical data of&#xD;
      Chinese patients. In addition, the overall incidence of acute phase response, the main&#xD;
      adverse event after the first infusion, in Chinese patients is higher than that in Caucasian&#xD;
      patients population. Moreover, the results of the similar drug clinical study in the Japanese&#xD;
      patients shown that the purpose of effective treatment for osteoporosis could be achieved&#xD;
      with half of the dosage in Caucasian population. Thus, it could be inferred from these that&#xD;
      the dosing regimen of zoledronic acid might be inappropriate in Chinese osteoporosis&#xD;
      patients. Therefore, the main purpose of this clinical trail is to compare the zoledronic&#xD;
      acid pharmacokinetic and pharmacodynamic characteristic of different doses in Chinese&#xD;
      postmenopausal subjects with low bone mass or osteoporosis and explore the best dosing&#xD;
      regimen in Chinese patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Zoledronic acid</measure>
    <time_frame>Predose, 30 minutes, 2 hours, 24 hours, day 7, day 29, 3 months, 6 months, 12 months, 24 months, and 36 months post dose</time_frame>
    <description>Zoledronic acid concentration in plasma and urine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of Zoledronic acid</measure>
    <time_frame>0-36 months</time_frame>
    <description>The observed maximum concentration following administration (Cmax) in plasma after zoledronic acid infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum concentration of Zoledronic acid</measure>
    <time_frame>0-36 months</time_frame>
    <description>The time to reach the maximum concentration after administration (Tmax) in plasma after zoledronic acid infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of Zoledronic acid</measure>
    <time_frame>0-36 months</time_frame>
    <description>The area under the concentration-time curve (AUC) in plasma after zoledronic acid infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>terminal half-life of Zoledronic acid</measure>
    <time_frame>0-36 months</time_frame>
    <description>The terminal half-life (t1/2) of zoledronic acid after administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>apparent clearance of Zoledronic acid</measure>
    <time_frame>0-36 months</time_frame>
    <description>The apparent clearance (CL/F) of zoledronic acid after administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>apparent volume of distribution of Zoledronic acid</measure>
    <time_frame>0-36 months</time_frame>
    <description>The apparent volume of distribution of zoledronic acid after administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of bone turnover markers</measure>
    <time_frame>0-36 months</time_frame>
    <description>Concentration-time profile of procollagen type 1 N-propeptide (P1NP), bone-specific alkaline phosphatase (ALP), osteocalcin (OCN), C-telopeptide (CTx), and tartrate-resistant acid phosphatase 5b (TRACP-5b) with unit of ng/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of 25(OH)D and FGF23</measure>
    <time_frame>0-36 months</time_frame>
    <description>Concentration determination of 25(OH)D and fibroblast growth factor 23 (FGF23) with unit of ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PTH concentration determination</measure>
    <time_frame>0-36 months</time_frame>
    <description>Assessment of the profile of parathyroid hormone (PTH)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum sclerostin concentration determination</measure>
    <time_frame>0-36 months</time_frame>
    <description>Concentration-time profile of sclerostin (SOST) after zoledronic acid infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic of zoledronic acid</measure>
    <time_frame>0-36 months</time_frame>
    <description>Assessment of lipid metabolism markers, such as low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol, and triglycerides.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic of zoledronic acid</measure>
    <time_frame>0-36 months</time_frame>
    <description>Assessment of fibroblast growth factor 19 (FGF19).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic of zoledronic acid</measure>
    <time_frame>0-36 months</time_frame>
    <description>Assessment of total bile acid.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic of zoledronic acid</measure>
    <time_frame>0-36 months</time_frame>
    <description>Assessment of bone mineral density at the lumbar spine, neck of femur, and total hip.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of immune indicator</measure>
    <time_frame>0-36 months</time_frame>
    <description>Changes in white blood cells(WBC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of immune indicator</measure>
    <time_frame>0-36 months</time_frame>
    <description>Changes in C reaction protein (CRP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of immune indicator</measure>
    <time_frame>0-36 months</time_frame>
    <description>Changes in interferon-γ (IFN-γ)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of immune indicator</measure>
    <time_frame>0-36 months</time_frame>
    <description>Changes in interleukin-6 (IL-6)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of immune indicator</measure>
    <time_frame>0-36 months</time_frame>
    <description>Changes in γδT cells activation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse event</measure>
    <time_frame>0-36 months</time_frame>
    <description>The occurrence time and severity of fracture. The occurrence time and severity of acute phase response. The occurrence time and severity of other adverse event.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>zoledronic acid 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Add 20 mL of Zoledronic acid injection (100mL : 5mg) with 80 mL of normal saline to 100 mL. Infusion 20 minutes with constant speed. Administration only once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>zoledronic acid 2.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Add 50 mL of Zoledronic acid injection (100mL : 5mg) with 50 mL of normal saline to 100 mL. Infusion 20 minutes with constant speed. Administration only once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>zoledronic acid 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion 100 mL of Zoledronic acid injection (100mL : 5mg) with constant speed in 20 minutes. Administration only once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion 100 mL of normal saline with constant speed in 20 minutes. Administration only once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid Injection</intervention_name>
    <description>Infusion 1mg zoledronic acid once.</description>
    <arm_group_label>zoledronic acid 1mg</arm_group_label>
    <other_name>Yigu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid Injection</intervention_name>
    <description>Infusion 2.5mg zoledronic acid once.</description>
    <arm_group_label>zoledronic acid 2.5mg</arm_group_label>
    <other_name>Yigu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid Injection</intervention_name>
    <description>Infusion 5mg zoledronic acid once.</description>
    <arm_group_label>zoledronic acid 5mg</arm_group_label>
    <other_name>Yigu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Infusion normal saline once.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Yigu Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chinese postmenopausal women&#xD;
&#xD;
          2. Aged between 60 and 70.&#xD;
&#xD;
          3. Bone mineral density (BMD) values of less than 1 standard deviations (SD) below the&#xD;
             normal adult mean.&#xD;
&#xD;
          4. Willing to participate in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to zoledronic acid or other bisphosphonate or zoledronic acid&#xD;
             formulation (excipients).&#xD;
&#xD;
          2. Secondary osteoporosis.&#xD;
&#xD;
          3. Receiving the following drugs that affect bone metabolism prior to randomization:&#xD;
&#xD;
        (1) intravenous biphosphonates or denosumab. (2) oral biphosphonates, parathyroid hormone&#xD;
        or its analogues, strontium, or fluoride within 12 months.&#xD;
&#xD;
        (3) glucocorticoid, steroids, immunosuppressive agents, calcitonin, calcitriol or its&#xD;
        analogues, thiazides diuretics, long-acting estrogen/progesterone, or statins within 3&#xD;
        months.&#xD;
&#xD;
        4. Combine other diseases affect bone metabolism: osteogenesis imperfecta, hyperthyroidism,&#xD;
        malignant tumors, Paget's disease, rheumatoid arthritis, osteomalacia, osteopetrosis,&#xD;
        ankylosing spondylitis, liver failure, or renal failure.&#xD;
&#xD;
        5. Hyperthyroidism or hypothyroidism during screening.&#xD;
&#xD;
        6. Treatment with any investigational drug within the past 3 months.&#xD;
&#xD;
        7. Creatinine clearance &lt; 35 mL/min.&#xD;
&#xD;
        8. 25(OH)D level&lt; 20 ng/mL.&#xD;
&#xD;
        9. Serum calcium level &lt; 2.0 mmol/L (8 mg/dL), or &gt;2.8 mmol/L (11.0 mg/dL).&#xD;
&#xD;
        10. Fever, severe infections, severe injuries, or major surgical operation within 30 days.&#xD;
&#xD;
        11. ECG corrected QT interval (QTc) &gt; 480 ms.&#xD;
&#xD;
        12. Pending invasive dental procedure or in progress.&#xD;
&#xD;
        13. History of smoking within 6 months.&#xD;
&#xD;
        14. Diabetes with fasting blood glucose ≥ 7.0 mmol/L, or glycated hemoglobin (HbA1c) &gt;6.3%.&#xD;
&#xD;
        15. History of drug or alcohol abuse.&#xD;
&#xD;
        16. History of stroke, cerebral ischemic stroke, or cerebral hemorrhage.&#xD;
&#xD;
        17. Any physiological or medical condition which, in the opinion of the investigator, would&#xD;
        preclude the participant from this trail.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunli Song, M.D.; Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qi Liu, Ph. D.</last_name>
    <phone>+8615501060136</phone>
    <email>liuqicpu@hotmail.com</email>
  </overall_contact>
  <reference>
    <citation>Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R; National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014 Oct;25(10):2359-81. doi: 10.1007/s00198-014-2794-2. Epub 2014 Aug 15. Erratum in: Osteoporos Int. 2015 Jul;26(7):2045-7.</citation>
    <PMID>25182228</PMID>
  </reference>
  <reference>
    <citation>Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int. 2003 May;14(3):225-34. Epub 2003 Apr 10.</citation>
    <PMID>12730746</PMID>
  </reference>
  <reference>
    <citation>Ding Y, Zeng JC, Yin F, Zhang CL, Zhang Y, Li SX, Liu X, Zhang C, Xue QY, Lin H, Pei FX. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis. Orthop Surg. 2017 Aug;9(3):284-289. doi: 10.1111/os.12338.</citation>
    <PMID>28960821</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>zoledronic acid</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>Chinese osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

